Evidence map›Paper›PMID 40643496›Full record

ArticleCells2025

COP1 Deficiency in BRAF

Ada Ndoja, Christopher M Rose, Eva Lin, Rohit Reja, Jelena Petrovic, Sarah Kummerfeld, Andrew Blair, Helen Rizos, Zora Modrusan, Scott Martin and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ada NdojaDepartment of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA.ORCID 0009-0007-2614-0318
Christopher M RoseDepartment of Proteomics and Genomics Technologies, Genentech, South San Francisco, CA 94080, USA.
Eva LinDepartment of Molecular Oncology, Genentech, South San Francisco, CA 94080, USA.
Rohit RejaDepartment of Computational Sciences, Genentech, South San Francisco, CA 94080, USA.
Jelena PetrovicDepartment of Proteomics and Genomics Technologies, Genentech, South San Francisco, CA 94080, USA.
Sarah KummerfeldDepartment of Computational Sciences, Genentech, South San Francisco, CA 94080, USA.ORCID 0000-0002-0089-2358
Andrew BlairDepartment of Computational Sciences, Genentech, South San Francisco, CA 94080, USA.
Helen RizosMelanoma Institute Australia, Wollstonecraft, NSW 2065, Australia.ORCID 0000-0002-2094-9198
Zora ModrusanDepartment of Proteomics and Genomics Technologies, Genentech, South San Francisco, CA 94080, USA.
Scott MartinDepartment of Molecular Oncology, Genentech, South San Francisco, CA 94080, USA.
Donald S KirkpatrickDepartment of Proteomics and Genomics Technologies, Genentech, South San Francisco, CA 94080, USA.
Amy HeidersbachDepartment of Molecular Biology, Genentech, South San Francisco, CA 94080, USA.
Tao SunDepartment of Molecular Biology, Genentech, South San Francisco, CA 94080, USA.
Benjamin HaleyDepartment of Molecular Biology, Genentech, South San Francisco, CA 94080, USA.
Ozge KarayelDepartment of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA.
Kim NewtonDepartment of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA.
Vishva M DixitDepartment of Physiological Chemistry, Genentech, South San Francisco, CA 94080, USA.ORCID 0000-0001-6983-0326

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant activation of the mitogen-activated protein kinase (MAPK) cascade promotes oncogenic transcriptomes. Despite efforts to inhibit oncogenic kinases, such as BRAFV600E, tumor responses in patients can be heterogeneous and limited by drug resistance mechanisms. Here, we describe patient tumors that acquired COP1 or DET1 mutations after treatment with the BRAF

Indexed as

Drug Resistance, NeoplasmMAP Kinase Signaling SystemMelanomaProtein Kinase InhibitorsProto-Oncogene Proteins B-rafUbiquitin-Protein LigasesCell Line, TumorDNA-Binding ProteinsHumansMutationTranscription FactorsVemurafenibBRAF protein, humanCOP1 protein, humanDNA-Binding ProteinsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafTranscription FactorsUbiquitin-Protein LigasesVemurafenibBRAFCOP1DET1melanomavemurafenib

Identifiers

PMID40643496
PMCPMC12249101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.